Danaher Corporation has announced a new partnership with researchers at Washington University School of Medicine in St. Louis. This collaboration, known as a Beacon project, aims to advance the development of plasma biomarkers for Alzheimer's disease. The initiative focuses on two primary objectives: identifying and validating new diagnostic markers for Alzheimer's, and enhancing the understanding of patient progression from mild cognitive impairment to more advanced stages of dementia. This partnership underscores Danaher's commitment to pioneering innovative diagnostic solutions to address the growing challenges posed by Alzheimer's disease.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。